[go: up one dir, main page]

NI200700058A - Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteína quinasa - Google Patents

Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteína quinasa

Info

Publication number
NI200700058A
NI200700058A NI200700058A NI200700058A NI200700058A NI 200700058 A NI200700058 A NI 200700058A NI 200700058 A NI200700058 A NI 200700058A NI 200700058 A NI200700058 A NI 200700058A NI 200700058 A NI200700058 A NI 200700058A
Authority
NI
Nicaragua
Prior art keywords
inhibitors
aminoheteroarilo
pirazol
compounds replaced
compounds
Prior art date
Application number
NI200700058A
Other languages
English (en)
Inventor
Jingrong Jean Cui
Lee Andrew Funk
Lei Jia
Pei-Pei Kung
Jerry Jialun Meng
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35677463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200700058(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NI200700058A publication Critical patent/NI200700058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan compuestos de fórmula 1, así como procedimientos para su síntesis y uso. Los compuestos preferidos son potentes inhibidores de la proteína quinasa c-Met, y son útiles en el tratamiento de trastornos del crecimiento celular anormal, tales como cánceres.
NI200700058A 2004-08-26 2007-02-23 Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteína quinasa NI200700058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60524404P 2004-08-26 2004-08-26
US69080305P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
NI200700058A true NI200700058A (es) 2008-03-07

Family

ID=35677463

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700058A NI200700058A (es) 2004-08-26 2007-02-23 Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteína quinasa

Country Status (43)

Country Link
US (1) US20060128724A1 (es)
EP (1) EP1784396B8 (es)
JP (1) JP4167295B2 (es)
KR (1) KR100869393B1 (es)
CN (1) CN101018780B (es)
AP (1) AP2332A (es)
AR (1) AR050529A1 (es)
AT (1) ATE492544T1 (es)
AU (1) AU2005276132B2 (es)
BR (1) BRPI0514537B8 (es)
CA (1) CA2577937C (es)
CR (2) CR8938A (es)
CY (1) CY1111138T1 (es)
DE (1) DE602005025499D1 (es)
DK (1) DK1784396T3 (es)
EA (1) EA011725B1 (es)
EC (1) ECSP077278A (es)
ES (1) ES2355923T3 (es)
GE (1) GEP20094845B (es)
GT (1) GT200500226A (es)
HN (1) HN2005000477A (es)
HR (1) HRP20110116T1 (es)
IL (1) IL181045A0 (es)
MA (1) MA28827B1 (es)
ME (1) ME01309B (es)
MX (1) MX2007002310A (es)
MY (1) MY139942A (es)
NI (1) NI200700058A (es)
NL (1) NL1029809C2 (es)
NO (1) NO338656B1 (es)
NZ (1) NZ552946A (es)
PA (1) PA8643201A1 (es)
PE (1) PE20060651A1 (es)
PL (1) PL1784396T3 (es)
PT (1) PT1784396E (es)
RS (1) RS51601B (es)
SI (1) SI1784396T1 (es)
SV (1) SV2006002208A (es)
TN (1) TNSN07071A1 (es)
TW (1) TWI300411B (es)
UY (1) UY29080A1 (es)
WO (1) WO2006021881A2 (es)
ZA (1) ZA200701281B (es)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103265477B (zh) * 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
US20070072908A1 (en) * 2005-06-08 2007-03-29 Japan Tobacco Inc. Heterocyclic compounds
EP1963302B1 (en) * 2005-12-05 2013-02-27 Pfizer Products Inc. Polymorphs of a c-met/hgfr inhibitor
KR101026676B1 (ko) * 2005-12-05 2011-04-04 화이자 프로덕츠 인코포레이티드 비정상 세포 성장의 치료 방법
MX2009004059A (es) 2006-10-23 2009-04-27 Sgx Pharmaceuticals Inc Triazoles biciclicos como moduladores de proteina cinasa.
GB0621607D0 (en) * 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
ES2396160T3 (es) 2006-12-14 2013-02-19 Bayer Intellectual Property Gmbh Derivados de DIHIDROPIRIDINA que utiliza como inhibidores de la proteina quinasa
WO2008088881A1 (en) 2007-01-19 2008-07-24 Xcovery, Inc. Kinase inhibitor compounds
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
US8263585B2 (en) 2007-05-04 2012-09-11 Novartis Ag Organic compounds
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
JP5973131B2 (ja) 2007-09-13 2016-08-23 コデクシス， インコーポレイテッド アセトフェノンの還元のためのケトレダクターゼポリペプチド
KR20100089090A (ko) 2007-10-25 2010-08-11 아스트라제네카 아베 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
WO2009099982A1 (en) * 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
EP2269993B1 (en) 2008-04-23 2013-02-27 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
KR101034351B1 (ko) * 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물
NZ590542A (en) 2008-06-19 2012-12-21 Xcovery Holding Co Llc Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
DE102009003975A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
US8269012B2 (en) * 2009-05-28 2012-09-18 Vertex Pharmaceuticals Incorporated Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
EP2534156A1 (en) * 2010-02-11 2012-12-19 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
BR112012020976A2 (pt) * 2010-02-22 2017-05-09 Glaxosmithkline Llc triazolonas como inibidores de ácido graxo sintase
US20120329826A1 (en) 2010-03-03 2012-12-27 OSI Pharmaceuticals,. LLC Substituted-5-aminopyrrolo/pyrazolopyridines
WO2011138751A2 (en) * 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
US8513238B2 (en) * 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
JP2013526570A (ja) 2010-05-14 2013-06-24 オーエスアイ・ファーマシューティカルズ，エルエルシー 縮合二環式キナーゼ阻害剤
KR101871436B1 (ko) 2010-05-17 2018-06-27 인코젠 쎄라퓨틱스 프라이빗 리미티드 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
CN101857594B (zh) * 2010-06-18 2013-04-03 南方医科大学 一种四氢吡啶并吲哚类化合物及其制备方法和应用
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2590982B1 (en) * 2010-07-09 2017-08-23 The Walter and Eliza Hall Institute of Medical Research Protein kinase inhibitors and methods of treatment
CN101967140A (zh) * 2010-09-14 2011-02-09 郑州泰基鸿诺药物科技有限公司 氘代克里唑蒂尼及其衍生物、制备方法和应用
WO2012048259A2 (en) 2010-10-08 2012-04-12 Xcovery Holding Company, Llc Substituted pyridazine carboxamide compounds
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
SG193982A1 (en) 2011-03-28 2013-11-29 Mei Pharma Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
CN102850328B (zh) * 2011-07-01 2014-12-24 苏州东南药业股份有限公司 吡啶类化合物、其制备方法、包含该化合物的药物组合物及其用途
CA2842841C (en) * 2011-07-27 2016-04-19 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as protein kinase inhibitors
US20160206608A1 (en) 2011-08-02 2016-07-21 Pfizer Inc. Crizotinib for use in the treatment of cancer
EP2758387A4 (en) * 2011-09-21 2015-03-11 Teligene Ltd Pyridine compounds as kinase inhibitors
CN103087050A (zh) * 2011-10-28 2013-05-08 山东轩竹医药科技有限公司 芳基激酶抑制剂
CA2863892C (en) 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
CN103304552B (zh) * 2012-03-09 2016-12-28 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
WO2013138210A1 (en) * 2012-03-14 2013-09-19 Ning Xi Substituted cyclic compounds and methods of use
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
CN103319468B (zh) * 2012-03-21 2016-07-13 广东东阳光药业有限公司 取代的螺双环化合物及其使用方法和用途
WO2013144191A1 (de) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
CN104321322A (zh) 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103373986B (zh) * 2012-04-22 2016-10-05 东南大学 克里唑替尼前药及其制备方法与用途
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
WO2013181251A1 (en) 2012-05-29 2013-12-05 Ratiopharm Gmbh Crizotinib hydrochloride salt in crystalline
GB201211310D0 (en) * 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
WO2014020467A2 (en) 2012-07-30 2014-02-06 Fresenius Kabi Oncology Ltd Process for the preparation of pyrazole substituted aminoheteroaryl compounds
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
US9446039B2 (en) 2012-08-27 2016-09-20 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Aminoheteroaryl compounds as MTH1 inhibitors
CN103720691A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
US20150299170A1 (en) * 2012-11-21 2015-10-22 Concert Pharmaceuticals, Inc. Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds
CN104918934B (zh) 2013-01-18 2017-12-22 霍夫曼-拉罗奇有限公司 3‑取代的吡唑及其作为dlk抑制剂的用途
CA2899968C (en) * 2013-02-02 2016-12-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-aminopyridine protein kinase inhibitor
CN103992307B (zh) 2013-02-16 2017-07-14 浙江九洲药物科技有限公司 一种克里唑替尼的制备方法
WO2014139391A1 (en) * 2013-03-11 2014-09-18 Teligene Ltd Substituted pyridine compounds as kinases inhibitors
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム，インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
SG11201506972PA (en) 2013-03-14 2015-10-29 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
CN104059054B (zh) * 2013-03-19 2018-11-20 浙江导明医药科技有限公司 用于治疗癌症的三级环状胺alk激酶抑制剂
WO2014203177A1 (en) * 2013-06-18 2014-12-24 Shilpa Medicare Limited Amorphous (r) -3- [1- (2, 6-dichloro-3-fluorophenyl) methoxy] -5- [1- (piperidin-4- yl) -1h-pyrazol-4-yl] pyridin-2-amine
CN104230890A (zh) * 2013-06-19 2014-12-24 信诺凯（北京）化工有限公司 吡啶-2-胺衍生物及其制法和药物组合物与用途
CN104650049B (zh) * 2013-08-28 2018-06-08 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
KR101598664B1 (ko) 2013-09-04 2016-03-02 씨제이헬스케어 주식회사 피롤로피리다진 유도체를 포함하는 단백질 키나제 억제제
WO2015034729A1 (en) * 2013-09-05 2015-03-12 Calitor Sciences, Llc Substituted pyridine compounds and methods of use
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3053923B1 (en) 2013-09-30 2018-04-11 Korea Research Institute of Chemical Technology Triazolopyrazine derivatives as tyrosin kinase inhibitors
WO2015148531A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2015172747A1 (en) * 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016044576A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
CN104402868B (zh) * 2014-11-04 2016-08-24 郑州泰基鸿诺医药股份有限公司 氘代克里唑蒂尼晶型及其制备方法
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016145383A1 (en) * 2015-03-11 2016-09-15 Board Of Regents, University Of Texas System Mth1 inhibitors for treating disease
AU2016251253B2 (en) 2015-04-24 2020-07-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
CN106279112A (zh) * 2015-06-12 2017-01-04 浙江九洲药业股份有限公司 一种克里唑替尼中间体及其制备方法和应用
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
CA3025019A1 (en) 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
TWI646094B (zh) 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN106632260B (zh) * 2016-09-29 2019-04-26 上海天慈生物谷生物工程有限公司 一种小分子激酶抑制剂的制备方法
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
CN111212643A (zh) 2017-08-14 2020-05-29 梅制药公司 联合疗法
CN110372664A (zh) * 2018-04-13 2019-10-25 华东理工大学 选择性jak2抑制剂及其应用
KR102207608B1 (ko) 2019-04-24 2021-01-26 윤종오 카르복실산으로 유기화된 규소 이온 복합체 및 복합체의 제조방법과 이를 이용한 제품
CN115745979B (zh) * 2021-11-11 2025-09-23 中国医学科学院医药生物技术研究所 一种蛋白靶向降解化合物及其用途
CA3258469A1 (en) 2022-07-04 2025-03-18 Chugai Seiyaku Kabushiki Kaisha DRUG ASSOCIATION
AU2023334709A1 (en) 2022-08-30 2025-03-13 Chugai Seiyaku Kabushiki Kaisha Combination drug

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI941572L (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE503496T1 (de) * 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) * 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JPH11512750A (ja) * 1996-06-27 1999-11-02 ファイザー インク． ２―（２―オキソ―エチリデン）―イミダゾリジン―４―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法
JPH11236333A (ja) * 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
IL141239A0 (en) * 1998-08-27 2002-03-10 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
DE69923849T2 (de) * 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
EP1006113A1 (en) * 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
TR200201296T2 (tr) * 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
US6586447B1 (en) * 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
EP1081137A1 (en) * 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
ATE259365T1 (de) * 1999-11-30 2004-02-15 Pfizer Prod Inc Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
EP1472237A4 (en) * 2002-02-06 2006-01-11 Yissum Res Dev Co BIOISOSTERS OF CATECHOL
JP2005538975A (ja) * 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
WO2004013091A2 (en) * 2002-08-01 2004-02-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
DE10307845A1 (de) * 2003-02-25 2004-09-02 Bayer Cropscience Gmbh Heterocyclische Amide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
CN103265477B (zh) * 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe

Also Published As

Publication number Publication date
PT1784396E (pt) 2011-01-27
CN101018780B (zh) 2012-01-11
EP1784396B1 (en) 2010-12-22
BRPI0514537B8 (pt) 2021-05-25
CR20120421A (es) 2012-09-14
CN101018780A (zh) 2007-08-15
IL181045A0 (en) 2007-07-04
GEP20094845B (en) 2009-11-25
KR100869393B1 (ko) 2008-11-21
AP2007003906A0 (en) 2007-02-28
NO20071320L (no) 2007-05-29
NL1029809C2 (nl) 2006-10-17
MY139942A (en) 2009-11-30
PL1784396T3 (pl) 2011-05-31
NL1029809A1 (nl) 2006-02-28
EP1784396B8 (en) 2011-04-20
ME01309B (me) 2013-12-20
RS51601B (sr) 2011-08-31
TWI300411B (en) 2008-09-01
TW200621751A (en) 2006-07-01
KR20070038569A (ko) 2007-04-10
WO2006021881A3 (en) 2006-05-18
SI1784396T1 (sl) 2011-03-31
MX2007002310A (es) 2007-05-08
CA2577937C (en) 2010-12-21
AP2332A (en) 2011-12-05
UY29080A1 (es) 2006-03-31
HRP20110116T1 (hr) 2011-03-31
DE602005025499D1 (de) 2011-02-03
ES2355923T3 (es) 2011-04-01
AU2005276132A1 (en) 2006-03-02
HN2005000477A (es) 2010-06-09
WO2006021881A2 (en) 2006-03-02
DK1784396T3 (da) 2011-02-14
NO338656B1 (no) 2016-09-26
PA8643201A1 (es) 2006-06-02
EA200700321A1 (ru) 2007-08-31
ECSP077278A (es) 2007-03-29
MA28827B1 (fr) 2007-08-01
PE20060651A1 (es) 2006-07-19
HK1105415A1 (en) 2008-04-03
US20060128724A1 (en) 2006-06-15
NZ552946A (en) 2010-09-30
CR8938A (es) 2007-08-14
BRPI0514537A (pt) 2008-06-17
BRPI0514537B1 (pt) 2020-05-12
GT200500226A (es) 2006-04-10
JP2008510788A (ja) 2008-04-10
CA2577937A1 (en) 2006-03-02
TNSN07071A1 (fr) 2008-06-02
EA011725B1 (ru) 2009-04-28
EP1784396A2 (en) 2007-05-16
AR050529A1 (es) 2006-11-01
AU2005276132B2 (en) 2011-09-29
JP4167295B2 (ja) 2008-10-15
ZA200701281B (en) 2008-12-31
CY1111138T1 (el) 2015-06-11
SV2006002208A (es) 2006-10-04
ATE492544T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
NI200700058A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteína quinasa
UY29081A1 (es) Compuestos de aminoheteroarilo enantioméricamente puros como inhibidores de proteína quinasa
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
CR9365A (es) Compuestos y metodos para la inhibicion de la protein-cinasa raf
CR11678A (es) Combinaciones de un conjugado anticuerpo-farmaco anti-her2 y agentes quimioterapeuticos y los metodos de uso
BRPI0514687A (pt) compostos amino heteroarila como inibidores de proteìna tirosina cinase
CR9677A (es) Derivados de pirrolo(2,3-b) piridina como inhibidores de proteina cinasa
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
ECSP088932A (es) Nuevos compuestos químicos
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
ECSP099823A (es) Nuevos compuestos químicos
CO6351782A2 (es) COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA
ECSP109942A (es) Nuevos herbicidas
ECSP10010361A (es) Derivados de piridazinona
MX2018001324A (es) Forma cristalina de base libre de lorlatinib.
ECSP11011133A (es) Nuevos herbicidas.
AR083751A1 (es) Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer
UY29591A1 (es) Aminopirimidinas como moduladores de quinasas
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn
CU23666B7 (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteína quinasa
DOP2005000154A (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
DOP2005000155A (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa.
CU23648B7 (es) Compuestos de aminoheteroarilo enantioméricamente puros como inhibidores de proteína quinasa